Brief Report: Acamprosate in Fragile X Syndrome

被引：54

作者：

Erickson, Craig A. ^{[1
,2
]}

Mullett, Jennifer E. ^{[1
,2
]}

McDougle, Christopher J. ^{[1
,2
]}

机构：

[1] Indiana Univ Sch Med, Dept Psychiat, Indianapolis, IN 46202 USA

[2] James Whitcomb Riley Hosp Children, Christian Sarkine Autism Treatment Ctr, Indianapolis, IN 46202 USA

来源：

JOURNAL OF AUTISM AND DEVELOPMENTAL DISORDERS | 2010年 / 40卷 / 11期

关键词：

Acamprosate; Fragile X syndrome; mGluR5; Language; Irritability; METABOTROPIC GLUTAMATE RECEPTORS; MENTAL-RETARDATION; OXIDATIVE STRESS; MOUSE MODEL; MICE; PROTEIN; MGLUR5; RESCUE; MPEP;

D O I：

10.1007/s10803-010-0988-9

中图分类号：

B844 [发展心理学（人类心理学）];

学科分类号：

040202 ;

摘要：

Glutamatergic dysfunction is implicated in the pathophysiology of fragile X syndrome (FXS). We report on the first trial of acamprosate, a drug with putative mGluR5 antagonism, in three adults with FXS and autism. Medical records describing open-label treatment with acamprosate in 3 patients with FXS and a comorbid diagnosis of autistic disorder were reviewed. In all three patients, acamprosate was associated with improved linguistic communication. Three patients received acamprosate over a mean 21.3 weeks of treatment. All patients showed global clinical benefit as rated with the Clinical Global Impressions-Improvement scale. Marked communication improvement was unexpected and has potential implications for the treatment of FXS, as well as idiopathic autism.

引用

页码：1412 / 1416

页数：5

共 30 条

[1]

al Qatari M, 2001, ALCOHOL CLIN EXP RES, V25, P1276, DOI 10.1097/00000374-200109000-00006

[2]

[Anonymous], PUBLICATION US DHEW

[3]

[Anonymous], 2000, DIAGN STAT MAN MENT, DOI DOI 10.1176/APPI.BOOKS.9780890425787

[4] The mGIuR theory of fragile X mental retardation [J].

Bear, MF ;

Huber, KM ;

Warren, ST .

TRENDS IN NEUROSCIENCES, 2004, 27 (07) :370-377

[5] A pilot open label, single dose trial of fenobam in adults with fragile X syndrome [J].

Berry-Kravis, E. ;

Hessl, D. ;

Coffey, S. ;

Hervey, C. ;

Schneider, A. ;

Yuhas, J. ;

Hutchison, J. ;

Snape, M. ;

Tranfaglia, M. ;

Nguyen, D. V. ;

Hagerman, R. .

JOURNAL OF MEDICAL GENETICS, 2009, 46 (04) :266-271

[6] Open-label treatment trial of lithium to target the underlying defect in fragile X syndrome [J].

Berry-Kravis, Elizabeth ;

Sumis, Allison ;

Hervey, Crystal ;

Nelson, Michael ;

Porges, Stephen W. ;

Weng, Ning ;

Weiler, Ivan Jeanne ;

Greenough, William T. .

JOURNAL OF DEVELOPMENTAL AND BEHAVIORAL PEDIATRICS, 2008, 29 (04) :293-302

[7] Metabotropic glutamate receptor 5 (mGluR5) regulation of ethanol sedation, dependence and consumption: relationship to acamprosate actions [J].

Blednov, Yuri A. ;

Harris, R. Adron .

INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2008, 11 (06) :775-793

[8] Prolonged epileptiform discharges induced by altered group I metabotropic glutamate receptor-mediated synaptic responses in hippocampal slices of a fragile X mouse model [J].

Chuang, SC ;

Zhao, WF ;

Bauchwitz, R ;

Yan, QJ ;

Bianchi, R ;

Wong, RKS .

JOURNAL OF NEUROSCIENCE, 2005, 25 (35) :8048-8055

[9] α-Tocopherol Protects Against Oxidative Stress in the Fragile X Knockout Mouse: an Experimental Therapeutic Approach for the Fmr1 Deficiency [J].

de Diego-Otero, Yolanda ;

Romero-Zerbo, Yanina ;

el Bekay, Rajaa ;

Decara, Juan ;

Sanchez, Lourdes ;

Rodriguez-de Fonseca, Fernando ;

del Arco-Herrera, Ignacio .

NEUROPSYCHOPHARMACOLOGY, 2009, 34 (04) :1011-1026

[10] Rescue of behavioral phenotype and neuronal protrusion morphology in Fmr1 KO mice [J].

de Vrij, Fernke M. S. ;

Levenga, Josien ;

Van der Linde, Herma C. ;

Koekkoek, Sebastiaan K. ;

De Zeeuw, Chris I. ;

Nelson, David L. ;

Oostra, Ben A. ;

Willemsen, Rob .

NEUROBIOLOGY OF DISEASE, 2008, 31 (01) :127-132

← 1 2 3 →